JP2006502119A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006502119A5 JP2006502119A5 JP2004522411A JP2004522411A JP2006502119A5 JP 2006502119 A5 JP2006502119 A5 JP 2006502119A5 JP 2004522411 A JP2004522411 A JP 2004522411A JP 2004522411 A JP2004522411 A JP 2004522411A JP 2006502119 A5 JP2006502119 A5 JP 2006502119A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- substituted
- formula
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 8
- 239000012453 solvate Substances 0.000 claims 8
- 125000004043 oxo group Chemical group O=* 0.000 claims 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 229910052801 chlorine Inorganic materials 0.000 claims 5
- 239000000460 chlorine Substances 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 4
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 4
- -1 cyano, methoxy, methoxycarbonyl Chemical group 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- 239000011737 fluorine Substances 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 239000003054 catalyst Substances 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 239000012442 inert solvent Substances 0.000 claims 3
- 230000008447 perception Effects 0.000 claims 3
- 229910052723 transition metal Inorganic materials 0.000 claims 3
- 150000003624 transition metals Chemical class 0.000 claims 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 0 *c1cnc(-c2n[n](Cc(cccc3)c3F)c3ncccc23)nc1 Chemical compound *c1cnc(-c2n[n](Cc(cccc3)c3F)c3ncccc23)nc1 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10232572A DE10232572A1 (de) | 2002-07-18 | 2002-07-18 | Neue 2,5-disubstituierte Pyrimidinderivate |
| PCT/EP2003/007238 WO2004009589A1 (de) | 2002-07-18 | 2003-07-07 | Neue 2,5-disubstituierte pyrimidinderivate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006502119A JP2006502119A (ja) | 2006-01-19 |
| JP2006502119A5 true JP2006502119A5 (https=) | 2006-08-31 |
Family
ID=30010152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004522411A Ceased JP2006502119A (ja) | 2002-07-18 | 2003-07-07 | 新規２，５−二置換ピリミジン誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7091198B1 (https=) |
| EP (1) | EP1525202B1 (https=) |
| JP (1) | JP2006502119A (https=) |
| AU (1) | AU2003257437A1 (https=) |
| CA (1) | CA2492723C (https=) |
| DE (2) | DE10232572A1 (https=) |
| ES (1) | ES2256779T3 (https=) |
| WO (1) | WO2004009589A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4605952B2 (ja) * | 2001-08-29 | 2011-01-05 | 株式会社日立製作所 | 蓄電装置及びその制御方法 |
| BRPI0409649A (pt) * | 2003-04-23 | 2006-04-25 | Pharmacia & Upjohn Co Llc | pirimidinonas e pirimidinotionas substituìdas como antagonistas de crf |
| US7399765B2 (en) | 2003-09-19 | 2008-07-15 | Abbott Laboratories | Substituted diazabicycloalkane derivatives |
| US20050065178A1 (en) * | 2003-09-19 | 2005-03-24 | Anwer Basha | Substituted diazabicycloakane derivatives |
| JPWO2005047286A1 (ja) * | 2003-11-13 | 2007-05-31 | 小野薬品工業株式会社 | スピロ複素環化合物 |
| CN101449388B (zh) * | 2006-03-02 | 2011-01-19 | 艾斯莫斯技术有限公司 | 光敏感面积与光不敏感面积的比例增加的光电二极管 |
| DE102007026392A1 (de) | 2007-06-06 | 2008-12-11 | Bayer Healthcare Ag | Lösungen für die Perfusion und Konservierung von Organen und Geweben |
| TW201004963A (en) * | 2008-07-03 | 2010-02-01 | Targacept Inc | Derivatives of oxabispidine as neuronal nicotinic acetylcholine receptor ligands |
| US20110053923A1 (en) | 2008-12-22 | 2011-03-03 | Astrazeneca | Chemical compounds 610 |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| DE102010040234A1 (de) * | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Verfahren zur Herstellung von 5-Flour-1H-pyrazolo[3,4-b]pyridin-3-carbonitril |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| DE102010043380A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Benzyl-substituierte Carbamate und ihre Verwendung |
| EP2453000A1 (en) * | 2010-11-08 | 2012-05-16 | Infineum International Limited | Lubricating Oil Composition comprising a hydrogenated imide derived from a Diels-Alder adduct of maleic anhydride and a furan |
| ES2603028T3 (es) | 2011-11-25 | 2017-02-23 | Adverio Pharma Gmbh | Procedimiento para la preparación de (Z)-alfa-fluoro-beta-amino-acrilaldehídos sustituidos |
| MX2015010725A (es) | 2013-02-21 | 2016-05-31 | Adverio Pharma Gmbh | Formas de metil {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo [3,4-b] piridino-3-il] pirimidino-5-il} metil carbamato. |
| EP3094327A1 (en) | 2014-01-13 | 2016-11-23 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
| MX2017014057A (es) | 2015-05-06 | 2018-04-10 | Bayer Pharma AG | El uso de estimuladores sgc, activadores gc, solos y combinaciones con inhibidores pde5 para el tratamiento de ulceras digitales (du) concomitante con esclerosis sistemica (ssc). |
| JP6849618B2 (ja) | 2015-07-23 | 2021-03-24 | バイエル・ファルマ・アクティエンゲゼルシャフト | 中性エンドペプチダーゼの阻害剤（ＮＥＰ阻害剤）および／またはアンジオテンシンＩＩ拮抗薬と組み合わせた可溶性グアニル酸シクラーゼ（ｓＧＣ）の刺激薬および／または活性化薬ならびにその使用 |
| CN105367567B (zh) * | 2015-11-18 | 2017-11-28 | 浙江京新药业股份有限公司 | 一种化合物及其在制备利奥西呱中的应用 |
| CN105367569B (zh) * | 2015-11-18 | 2017-10-27 | 浙江京新药业股份有限公司 | 一种化合物及其作为利奥西呱中间体的应用 |
| US20180344735A1 (en) | 2015-12-14 | 2018-12-06 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DYSFUNCTION |
| EP3525779B1 (de) | 2016-10-11 | 2024-06-05 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend den sgc stimulator vericuguat und den mineralcorticoid-rezeptor-antagonist finerenone |
| CN109890379A (zh) | 2016-10-11 | 2019-06-14 | 拜耳制药股份公司 | 包含sGC活化剂和盐皮质激素受体拮抗剂的组合产品 |
| CN110267949A (zh) | 2016-11-08 | 2019-09-20 | 塞科里昂医疗股份有限公司 | sGC刺激剂 |
| EP3554488A2 (en) | 2016-12-13 | 2019-10-23 | Cyclerion Therapeutics, Inc. | Use of sgc stimulators for the treatment of esophageal motility disorders |
| EP3793553A1 (en) | 2018-05-15 | 2021-03-24 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
| KR20250141845A (ko) | 2018-07-11 | 2025-09-29 | 티센토 쎄라퓨틱스 인크. | 미토콘드리아 장애의 치료를 위한 sGC 자극제의 용도 |
| WO2020164008A1 (en) | 2019-02-13 | 2020-08-20 | Bayer Aktiengesellschaft | Process for the preparation of porous microparticles |
| CN112457308B (zh) * | 2019-09-09 | 2024-01-02 | 上海长森药业有限公司 | 新型三环芳香杂环化合物，及其制备方法、药物组合物和应用 |
| CN118772140B (zh) * | 2023-04-07 | 2026-04-17 | 四川大学 | 一类化合物及其在治疗hDHODH介导的疾病中的用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19649460A1 (de) * | 1996-11-26 | 1998-05-28 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834045A1 (de) * | 1998-07-29 | 2000-02-03 | Bayer Ag | (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin |
| DE19834047A1 (de) * | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19846514A1 (de) * | 1998-10-09 | 2000-04-20 | Bayer Ag | Neue Heterocyclyl-methyl-substituierte Pyrazole |
| DE10054278A1 (de) * | 2000-11-02 | 2002-05-08 | Bayer Ag | Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Osteoporose |
| ES2231581T3 (es) * | 2000-11-22 | 2005-05-16 | Bayer Healthcare Ag | Nuevos derivados de pirazolopiridina sustituidos con lactama. |
| AR031176A1 (es) * | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| DE10057754A1 (de) * | 2000-11-22 | 2002-05-23 | Bayer Ag | Neue Sulfonamid-substituierte Pyrazolopyridinderivate |
-
2002
- 2002-07-18 DE DE10232572A patent/DE10232572A1/de not_active Withdrawn
-
2003
- 2003-07-07 ES ES03764943T patent/ES2256779T3/es not_active Expired - Lifetime
- 2003-07-07 EP EP03764943A patent/EP1525202B1/de not_active Expired - Lifetime
- 2003-07-07 WO PCT/EP2003/007238 patent/WO2004009589A1/de not_active Ceased
- 2003-07-07 AU AU2003257437A patent/AU2003257437A1/en not_active Abandoned
- 2003-07-07 US US10/521,538 patent/US7091198B1/en not_active Expired - Fee Related
- 2003-07-07 DE DE50302202T patent/DE50302202D1/de not_active Expired - Lifetime
- 2003-07-07 CA CA2492723A patent/CA2492723C/en not_active Expired - Fee Related
- 2003-07-07 JP JP2004522411A patent/JP2006502119A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006502119A5 (https=) | ||
| CA2492723A1 (en) | Novel 2,5-disubstituted pyrimidine derivatives | |
| JP2005538111A5 (https=) | ||
| JP2006524222A5 (https=) | ||
| JP2010510999A5 (https=) | ||
| RU2007105350A (ru) | 3-(гетероарилокси)-2-алкил-1-азабициклоалкильные производные, как лиганды альфа-7-nachr (никотиновых ацетилхолиновых рецепторов), предназначенные для лечения заболеваний центральной нервной системы | |
| JP2007516983A5 (https=) | ||
| JP2008526999A5 (https=) | ||
| RU2006101824A (ru) | 6-ариламино-5-циано-4-пиримидионы | |
| JP2007524696A5 (https=) | ||
| JP2013509392A5 (https=) | ||
| RU95117585A (ru) | ПРОИЗВОДНЫЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ | |
| JP2007501779A5 (https=) | ||
| JP2011506501A5 (https=) | ||
| EA200300718A1 (ru) | Производные 3-индолина, которые могут применяться при лечении психиатрических и неврологических расстройств | |
| JP2006508979A5 (https=) | ||
| RU2007130144A (ru) | Гетероциклические соединения в качестве антагонистов cccr2b | |
| CA2524900A1 (en) | 6-cyclylmethyl- and 6-alkylmethyl-substituted pyrazolopyrimidines | |
| JP2004507527A5 (https=) | ||
| JP2007522159A5 (https=) | ||
| JP2005533052A5 (https=) | ||
| JP2007538031A5 (https=) | ||
| JP2004525183A5 (https=) | ||
| JP2005502636A5 (https=) | ||
| RU2006129164A (ru) | Цианопиримидиноны |